25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
Authors
Keywords
-
Journal
GUT
Volume -, Issue -, Pages gutjnl-2019-320022
Publisher
BMJ
Online
2021-01-13
DOI
10.1136/gutjnl-2019-320022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis
- (2020) S Ben-Horin et al. Journal of Crohns & Colitis
- S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study
- (2020) Silvio Danese et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
- (2019) Byong Duk Ye et al. LANCET
- Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
- (2019) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study
- (2019) Sophie E. Berends et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients
- (2019) Anne S. Strik et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn’s Disease Compared with Reactive Monitoring
- (2019) Amit Assa et al. GASTROENTEROLOGY
- Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
- (2019) Nicholas A Kennedy et al. Lancet Gastroenterology & Hepatology
- Letter: should we intensify infliximab in acute severe ulcerative colitis?
- (2019) David Laharie et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
- (2019) Aleksejs Sazonovs et al. GASTROENTEROLOGY
- Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry
- (2018) Geert D’Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease
- (2018) Kenji Watanabe et al. Clinical Gastroenterology and Hepatology
- Acute Liver Failure from Tumor Necrosis Factor-α Antagonists: Report of Four Cases and Literature Review
- (2018) Beverley Kok et al. DIGESTIVE DISEASES AND SCIENCES
- Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
- (2018) Geert D’Haens et al. GASTROENTEROLOGY
- Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy—a Post-hoc analysis
- (2018) Jean Frederic Colombel et al. Clinical Gastroenterology and Hepatology
- Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy
- (2018) Toer W. Stevens et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
- (2017) Magali Lemaitre et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme
- (2017) Violeta Razanskaite et al. Journal of Crohns & Colitis
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
- (2016) Louise K Mercer et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
- (2016) Johannan F. Brandse et al. Clinical Gastroenterology and Hepatology
- Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
- (2016) Miguel Regueiro et al. GASTROENTEROLOGY
- The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
- (2016) Geoffrey C. Nguyen et al. GASTROENTEROLOGY
- Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study
- (2016) Lisa J. T. Smits et al. Journal of Crohns & Colitis
- Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis
- (2015) P. De Cruz et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease
- (2015) Isabelle Cleynen et al. ANNALS OF INTERNAL MEDICINE
- An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
- (2015) David J. Gibson et al. Clinical Gastroenterology and Hepatology
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease
- (2015) Paolo Biancheri et al. GASTROENTEROLOGY
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Crohn's disease management after intestinal resection: a randomised trial
- (2015) Peter De Cruz et al. LANCET
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI)
- (2013) Pieter Dewint et al. GUT
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children
- (2012) Jeffrey S. Hyams et al. GASTROENTEROLOGY
- Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
- (2012) Paul Rutgeerts et al. GASTROENTEROLOGY
- Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
- (2012) Xavier Hébuterne et al. GUT
- Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease
- (2012) S. Schreiber et al. Journal of Crohns & Colitis
- Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis
- (2011) Jeffrey Hyams et al. Clinical Gastroenterology and Hepatology
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
- (2010) Stefan Schreiber et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
- (2009) Filip Baert et al. GASTROENTEROLOGY
- Adalimumab for the treatment of fistulas in patients with Crohn's disease
- (2009) J-F Colombel et al. GUT
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started